Though circulating AGXT has not been previously reported as a biomarker of diet or metabolic disease, impaired expression of the AGXT gene may contribute to the development of atherosclerosis [56], and AGXT in liver tissue may be a biomarker for hepatocellular carcinoma [57]. This evidence concerns the gene AGXT and metabolic disease.